
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 11/1/25**
(See policy history boxes for previous effective dates)

Title: Phrenic Nerve Stimulation for Central Sleep Apnea

Description

Central sleep apnea (CSA) is characterized by sleep-disordered breathing due to diminished or absent respiratory effort. Central sleep apnea may be idiopathic or secondary (associated with a medical condition, drugs, or high altitude breathing). The use of positive airway pressure devices is currently the most common form of therapy for CSA. An implantable device that stimulates the phrenic nerve in the chest is a potential alternative treatment. The battery-powered device sends signals to the diaphragm in order to stimulate breathing and normalize sleep-related breathing patterns.

Medical Policy Statement

- The use of phrenic nerve stimulation for the treatment of central sleep apnea is considered **experimental / investigational**. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.
-

Inclusionary and Exclusionary Guidelines

NA

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

NA

Other codes (investigational, not medically necessary, etc.):

33276	33277	33278	33279	33280	33281
33287	33288	93150	93151	93152	93153
C1823					

Note: Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.

Background

Central Sleep Apnea

Central sleep apnea (CSA) is characterized by repetitive cessation or decrease in both airflow and ventilatory effort during sleep. CSA may be idiopathic or secondary (associated with a medical condition such as congestive heart failure, drugs, or high altitude breathing). Apneas associated with Cheyne-Stokes respiration are common among patients with heart failure (HF) or who have had strokes, and account for about half of the population with CSA. CSA is less common than obstructive sleep apnea. Based on analyses of a large community-based cohort of participants 40 years of age and older in the Sleep Heart Health Study, the estimated prevalence of CSA and obstructive sleep apnea are 0.9% and 47.6%, respectively.¹ Risk factors for CSA include age (>65 years), male gender, history of HF, history of stroke, other medical conditions (acromegaly, renal failure, atrial fibrillation, low cervical tetraplegia, and primary mitochondrial diseases), and opioid use. Individuals with CSA have difficulty maintaining sleep and therefore experience excessive daytime sleepiness, poor concentration, morning headaches, and are at higher risk for accidents and injuries.

Treatment

The goal of treatment is to normalize sleep-related breathing patterns. Because most cases of CSA are secondary to an underlying condition, central nervous system pathology, or medication side effects, treatment of the underlying condition or removal of the medication may improve CSA. Treatment recommendations differ depending on the classification of CSA as either hyperventilation-related (most common, including primary CSA and those relating to HF or high altitude breathing) or hypoventilation-related (less common, relating to central nervous system diseases or use of nervous system suppressing drugs such as opioids).

For individuals with hyperventilation-related CSA, continuous positive airway pressure (CPAP) is considered first-line therapy. Due to CPAP discomfort, patient compliance may become an issue. Supplemental oxygen during sleep may be considered for patients experiencing hypoxia

during sleep or who cannot tolerate CPAP. Patients with CSA due to HF and with an ejection fraction > 45% and who are not responding with CPAP and oxygen therapy, may consider bilevel positive airway pressure or adaptive servo-ventilation (ASV) as second-line therapy. Bilevel positive airway pressure devices have two pressure settings, one for inhalation and one for exhalation. ASV uses both inspiratory and expiratory pressure, and titrates the pressure to maintain adequate air movement. However, a clinical trial reported increased cardiovascular mortality with ASV in patients with CSA due to HF and with an ejection fraction <45%,² and therefore, ASV is not recommended for this group.

For individuals with hypoventilation-related CSA, first-line therapy is bilevel positive airway pressure.

Pharmacologic therapy with a respiratory stimulant may be recommended to patients with hyper- or hypoventilation CSA who do not benefit from positive airway pressure devices, though close monitoring is necessary due to the potential for adverse effects such as rapid heart rate, high blood pressure, and panic attacks.

Phrenic Nerve Stimulation

Several phrenic nerve stimulation systems are available for patients who are ventilator dependent. They stimulate the phrenic nerve in the chest which sends signals to the diaphragm to restore a normal breathing pattern. Currently, there is one phrenic nerve stimulation device approved by the U.S. Food and Drug Administration (FDA) for CSA, the remedē System (Zoll Medical). A cardiologist implants the battery powered device under the skin in the right or left pectoral region using local anesthesia. The device has two leads, one to stimulate a phrenic nerve (either the left pericardiophrenic or right brachiocephalic vein) and one to sense breathing. The device runs on an algorithm that activates automatically at night when the patient is in a sleeping position, and suspends therapy when the patient sits up. Patient-specific changes in programming can be conducted externally by a programmer.

Summary of Evidence

For individuals with CSA who receive phrenic nerve stimulation, the evidence includes a systematic review, one randomized controlled trial (RCT) and observational studies. Relevant outcomes are change in disease status, functional outcomes, and quality of life. The RCT compared the use of phrenic nerve stimulation to no treatment among patients with CSA of various etiologies. All patients received implantation of the phrenic nerve stimulation system, with activation of the system after 1 month in the intervention group and activation after 6 months in the control group. Activation is delayed one month after implantation to allow for lead healing. At 6 months follow-up, the patients with the activated device experienced significant improvements in several sleep metrics and quality of life measures. At 12 months follow-up, patients in the activated device arm showed sustained significant improvements from baseline in sleep metrics and quality of life. A subgroup analysis of patients with heart failure combined 6- and 12-month data from patients in the intervention group and 12- and 18-month data from the control group. Results from this subgroup analyses showed significant improvements in sleep metrics and quality of life at 12 months compared with baseline. Results from observational studies supported the results of the RCT. An invasive procedure would typically be considered only if non-surgical treatments had failed, but there is limited data in which phrenic nerve stimulation was evaluated in patients who had failed the current standard of care,

positive airway pressure or respiratory stimulant medication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Phrenic Nerve Stimulation for Central Sleep Apnea

Review of Evidence

Systematic Reviews

Wang et al (2024) conducted a meta-analysis to evaluate the efficacy of PNS in individuals with CSA.³ They conducted a systematic review up to December of 2021 and included 10 publications of RCTs and observational studies. Nine studies (n=351) reported AHI before and after PNS with a standard mean difference of -2.24 (95% CI: -3.11 to -1.36; p<.00001). Seven studies (n=332) reported CAI with a standard mean difference of -2.32 (95% CI: -3.17 to -1.47; p<.00001). Six studies (n=281) reported arousal index with a standard mean difference of -1.79 (95% CI: -2.74 to -0.85; p<.00001). Four studies (n=173) reported T90 with a standard mean difference of -0.54 (95% CI: -1.26 to 0.19; p<.00001). Three studies (n=104) reported sleep efficiency with a standard mean difference of 0.22 (95% CI: -0.26 to 0.69; p=.07). And 4 studies (n=186) reported ESS with a standard mean difference of -0.73 (95% CI: -1.59 to 0.14; p<.00001). A limitation of the meta-analysis is 4 of the publications used the same study cohort and another 2 publications used the same study cohort. The authors conclude the results of the meta-analysis indicates PNS may improve CSA, however, larger randomized studies are

needed to assess long-term effects of PNS. Details on the systematic review are in Tables 2 to 4.

Table 2. Comparison of Studies Included in Systematic Reviews & Meta-Analyses

Study	Wang et al (2024) ³
Costanzo et al (2021) ⁴	●
Oldenburg et al (2020) ⁵	●
Costanzo et al (2018) ⁶	●
Zhang et al (2017) ⁷	●
Fox et al (2017) ⁸	●
Jagielski et al (2016) ⁹	●
Costanzo et al (2016) ¹⁰	●
Abraham et al (2015) ¹¹	●
Ponikowski et al (2012) ¹²	●
Zhang et al (2012) ¹³	●

a. This study was identified in the systematic review, but was not included in the overall meta-analyses.

Table 3. Systematic Reviews & Meta-Analyses Characteristics

Study	Dates	Trials	Participants ¹	N (Range)	Design	Duration
Wang et al (2024) ³	Up to December 2021	10	Individuals with CSA	580 (3 to 151)	RCTs and observational	1 night to 5 years

RCT: randomized controlled trial.

Table 4. Systematic Reviews & Meta-Analyses Results

Study	AHI	CAI	Arousal Index	T90	Sleep efficiency	ESS
Wang et al (2024) ³						
Total N	351	332	281	173	104	186
Pooled effect (95% CI)	SMD, -2.24 (-3.11 to -1.36)	SMD, -2.32 (-3.17 to -1.47)	SMD, -1.79 (-2.74 to -0.85)	SMD, -0.54 (-1.26 to 0.19)	SMD, 0.22 (-0.26 to 0.69)	SMD, -0.73 (-1.59 to 0.14)
I ²	96%	95%	96%	90%	63%	93%

AHI: Apnea-Hypopnea Index; CAI: central apnea index; CI: confidence interval; ESS: Epworth Sleepiness Scale; T90: percent of sleep with O₂ saturation <90%.

Randomized Controlled Trial

Costanzo et al (2015) provided background and methodologic details of the remedē System Pivotal Trial.¹⁴ The trial is a prospective, multicenter, randomized, open-label controlled trial comparing transvenous unilateral phrenic nerve stimulation with no stimulation in patients with CSA of various etiologies (Table 5). All patients received implantation of the phrenic nerve stimulation system, with activation of the system after 1 month in the intervention group (n=73) and activation after 6 months in the control group (n=78). Activation is delayed one month after implantation to allow for lead healing. The primary efficacy endpoint is percentage of patients achieving a reduction in AHI of 50%, as interpreted from polysomnography by an assessor blinded to the treatment arm. The reduction of 50% was based on assessments showing that a 50% reduction in AHI is associated with reduced mortality risk and is therefore clinically

meaningful. Secondary endpoints include mean reductions in CAI, AHI, arousal index, oxygen desaturation index, and ESS. Of the 151 patients in the trial, 64% had heart failure (HF), 42% had atrial fibrillation, and a mean left ventricular ejection fraction of 39.6.

Costanzo et al (2016) reported the 6-month per protocol comparative results for the treatment and control groups (Table 6).¹⁰ Twelve, 24-, and 36-month results for the intervention group are shown in Table 7. Adverse events were reported in 9% of the intervention group and 8% of the control group (for example, implant site infection, implant site hematoma, and lead dislodgement). Non-serious therapy-related discomfort was reported in 27 (37%) of the intervention group, with all but 1 case resolved by system reprogramming. At 6 months follow-up, 15 of the 73 (21%) in the treatment group were excluded due to no 6-month data (n=9: unrelated death, device explant, missed visit, study exit), failed inclusion criteria (n=3), unsuccessful implant (n=2), therapy programmed off (n=1).

At the 12-month follow-up, an additional 4 patients were lost due to unrelated death, device explant, patient refusal, and missed visit. Results from the remaining 54 patients in the intervention group at 12 months are summarized in Table 7.¹⁵ Subgroup analyses showed consistent improvements in percent experiencing more than 50% AHI reductions from treatment across all of the following subgroups: age (< 65, 65 to < 75, and > 75), gender, HF (yes/no), defibrillator (yes/no), AHI severity (moderate/severe), and atrial fibrillation (yes/no). Follow-up at 24 months was available for 42 patients in the treatment group, while 22 patients in the treatment group and 28 patients in the control arm had reached 36-month follow-up at the time of study closure.⁶ Central apnea events remained low throughout follow-up with a median time to battery depletion of 39.4 months. Serious adverse events related to the implant procedure, device, or delivered therapy occurred in 10% of patients through the 24-month visit. All were reported to be resolved with remedē System revisions or programming. At the 5-year follow-up (N=52), AHI events remained low (median=17 events/hour) and ESS improved by a median of 3 points.⁷ A total of 14% of patients reported a serious adverse event, but no long-term harm or device-related death occurred.

Several post hoc analyses have been reported from the remedē System Pivotal Trial further investigating the effects of transvenous phrenic nerve stimulation. Baumert et al (2023) investigated treatment effect on the change in episodic hypoxemic burden between baseline and 6 months.¹⁷ They found the treatment group (n=72) compared to the control group (n=62) had reduced oxygen desaturation index (ODI) (-15.85 ± 1.99 1/h vs. 1.32 ± 1.85 1/h; $p<.0001$) and shortened T90 (-3.81 ± 1.23 vs. 0.49 ± 1.14 ; $p=.0121$). In another paper by Baumert et al (2023) they investigated the effect of treatment on nocturnal heart rate perturbations between baseline and 6 months.¹⁸ They found the treatment group (n=22) compared to the control group (n=26) had reduced cyclical heart rate variations in the very low-frequency power index across rapid eye movement (REM) ($4.12 \pm 0.79\%$ vs. $6.87 \pm 0.82\%$; $p=.02$) and non-rapid eye movement (NREM) sleep ($5.05 \pm 0.68\%$ vs. $6.74 \pm 0.70\%$; $p=.08$). They also found normalized low-frequency power was reduced in the treatment arm in REM (0.67 ± 0.03 n.u. vs. 0.77 ± 0.03 n.u.; $p=.02$) and NREM sleep (0.70 ± 0.02 n.u. vs. 0.76 ± 0.02 n.u.; $p=.03$). Hartmann et al (2023) studied the effects of treatment on sleep microstructure.¹⁹ They analyzed polysomnography data from baseline and 6 months. The treatment group (n=57) compared to controls (n=64) showed a decrease in the frequency of A2+A3 phases (-5.86 ± 11.82 vs. 0.67 ± 15.25 ; $p=.006$) and an increase in frequency of A1 phases (2.57 ± 11.67 vs. -2.47 ± 10.60 ; $p=.011$). Change in cyclic alternating pattern (CAP) rate at follow-up was comparable between

both groups. The authors concluded transvenous phrenic nerve stimulation may affect sleep microstructure, however, further studies are needed to better understand these mechanisms. Samii et al (2023) investigated sex differences in treatment effect over 12 months.²⁰ They found females (n=16) and males (n=135) experienced comparable improvements in CSA metrics, including improved sleep quality and architecture. At 12 months compared to baseline, females had improved AHI (median (Q1, Q3): -21 (-24, -10) events/hour; p=.002), CAI (median (Q1, Q3): -14 (-21, -10) events/hour; p=.002), and ESS scores (median (Q1, Q3): -2 (-9, -1) points; p=.008), and males had improved AHI (median (Q1, Q3): -22 (-40, -6) events/hour; p<.001), CAI (median (Q1, Q3): -21 (-35, -12) events/hour; p<.001), and ESS scores (median (Q1, Q3): -3 (-7, 0) points; p<0.001). However, this study was limited by the small number of females and the study was not powered to detect sex-specific differences in outcomes. Abraham et al (2024) conducted a post hoc, retrospective, subgroup analysis of patients with heart failure from this cohort (n=96).²¹ The analysis used the win ratio (WR) hierarchy to compare all patients in the treatment group (n=48) to the control group (n=48). Five subjects in the treatment group exited the trial prior to therapy initiation and were excluded from the WR analysis. The WR hierarchy included three components: longest survival, lowest heart failure (HF) hospitalization rate, and a ≥ 2 -category difference in Patient Global Assessment (PGA) at 6 months. They found that more patients in the treatment group experienced clinical benefit compared with the control group (WR: 4.92; 95% CI: 2.27 to 10.63; p<.0001). The authors noted limitations including the retrospective nature of the analysis, the small number of subjects, and the potential impact of new HF treatments on the applicability of the results.

Table 5. Summary of Key RCT Characteristics

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
					Intervention	Control
Costanzo (2015) ¹⁴	Germany, Poland, United States	31	2013-2015	Adult patients with moderate to severe CSA of various etiologies confirmed by PSG etiologies confirmed by PSG ^a and medically stable ^b	Implanted phrenic nerve stimulator (remedē system) activated at 1 month postprocedure (n=73, 58 analyzed)	Implanted phrenic nerve stimulator (remedē system) activated at 6 months postprocedure (n=78, 73 analyzed)
Baumert et al (2023) ¹⁷	NR	31	NR	Adult patients with moderate to severe CSA of various etiologies confirmed by PSG ^a and who had PSG data at the visit of interest	Implanted phrenic nerve stimulator (remedē system) on (n=72)	Implanted phrenic nerve stimulator (remedē system) off (n=62)

AHI: apnea-hypopnea index; CSA: central sleep apnea; PSG: polysomnography; RCT: randomized controlled trial.

a AHI >20 events/hr; CAI >50% of all apneas, with >30 central apnea events; OAI <20% of all AHI

b For 30 days prior to baseline testing: no hospitalizations for illness, no breathing mask-based therapy, and on stable medications and therapies.

Table 6. Summary of Key RCT Results^a

Study	Baseline	6-Month	Change from Baseline	Between Group Difference

Costanzo (2015, 2016) ^{14,10}				
>50% AHI reduction				
Treatment	NA	51% (39% to 64%)	NA	
Control	NA	11% (5% to 20%)	NA	41% (25% to 54%)
AHI				
Treatment	49.7 ± 18.9	25.9 ± 20.5	-23.9 ± 18.6	
Control	43.9 ± 17.3	45.0 ± 20.3	1.1 ± 17.6	-25.0 ± 18.1
CAI				
Treatment	31.7 ± 18.6	6.0 ± 9.2	-25.7 ± 18.0	
Control	26.2 ± 16.2	23.3 ± 17.4	-2.9 ± 17.7	-22.8 ± 17.8
PGA^b				
Treatment	NA	60% (47% to 73%)	NA	
Control	NA	6% (2% to 14%)	NA	55% (40% to 68%)
ESS				
Treatment	10.7 ± 5.3	7.1 ± 4.1	-3.6 ± 5.6	
Control	9.3 ± 5.7	9.4 ± 6.1	0.1 ± 4.5	-3.7 ± 5.0
Baumert et al (2023) ¹⁷				
ODI				
Treatment	NA	23.70 ± 1.99	-15.85 ± 1.99	NA
Control	NA	40.87 ± 1.85	1.32 ± 1.85	NA
T90				
Treatment	NA	7.96 ± 1.23	-3.81 ± 1.23	NA
Control	NA	12.26 ± 1.14	0.49 ± 1.14	NA

AHI: Apnea-Hypopnea Index; CAI: central apnea index; CI: confidence interval; ESS: Epworth Sleepiness Scale; NA: not applicable; ODI: oxygen desaturation index; PGA: Patient Global Assessment; RCT: randomized controlled trial; T90: percent of sleep with O₂ saturation <90%.

^a Data are presented as either % (95% CIs) or mean (standard deviation).

^b Patients with marked or moderate improvement in 7-point quality of life scale.

Costanzo et al (2018) provided 12-months follow-up results for the subgroup of patients in the Pivotal Trial who had HF.²² Pooling of results was possible by using 6 and 12-month data from the intervention group and 12 and 18-month data from the control group (the phrenic nerve stimulator was activated in the control group 6 months after implantation). At baseline, 96 of the patients in the trial had HF. By the six-months follow-up, there had been four deaths, one explant, and five withdrew from the study. By the 12-months follow-up, there had been an

additional 5 deaths, 1 explant, and 1 withdrawal, as well as 4 missing the final visit. Results at 6 and 12 months follow-up for the subgroup of patients with HF are summarized in Table 7. Hill et al (2023) also conducted a subgroup analysis in individuals with CSA and HF (n=75) from the Pivotal Trial, investigating the effect of treatment on sleep, quality of life, and symptoms between baseline and 12 months using self-reported questionnaires.²² Improvements were seen in 69% of individuals in ESS scores, 60% of individuals in Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and 53% of individuals in Fatigue Severity Score (FSS) scores.

Table 7. Summary of Treatment Arm Results at Follow-up

	Baseline	6-Month	12-Month	24-Month Median [IQR]	36-Month Median [IQR]	Paired Change, Baseline to 12- Month Month Mean (95% CI)
Costanzo (2018) ^{15,16}						
Treatment arm alone, N	58	58	54	42	22 ^a	54
AHI	49.7 ± 18.9	25.9 ± 20.5	23.0 ± 21.9	16 [7, 37]	13 [8, 37]	-25.4 (-44.4 to -11.4)
CAI	31.7 ± 18.6	6.0 ± 9.2	3.4 ± 6.9	0 [0, 3]	1 [0, 3]	-26.0 (-40.2 to -14.6)
OAI	2.1 ± 2.2	6.3 ± 7.0	4.5 ± 5.1	3 [0, 8]	4 [1, 11]	0.9 (-0.5 to 4.4)
PGA ^b	NA	60% (47% to 72%)	60% (47% to 72%)			NA
ESS	10.7 ± 5.3	7.1 ± 4.1	6.5 ± 3.5			-4.0 (-7.0 to -1.0)
Costanzo (2018) ²²						
Pooled HF subgroup, N	96	86	75			79
>50% AHI reduction	NA	53% (42% to 64%)	57% (45% to 68%)			NA
AHI	47.1 ± 18.5	25.2 ± 14.2	3.5 ± 6.5			-19.9 (-34.6 to -11.8)
CAI	26.2 ± 17.7	4.1 ± 6.0	3.4 ± 6.9			-26.0 (-40.2 to -14.6)
PGA ^b	NA	58% (NR)	55% (NR)			NA
ESS	8.9 ± 5.1	6.2 ± 4.1	6.1 ± 3.7			-2.0 (-5.0 to 0.0)

AHI: Apnea-Hypopnea Index; CAI: central apnea index; CI: confidence interval; ESS: Epworth Sleepiness Scale; IQR: interquartile range; HF: heart failure; NA: not applicable; NR: not reported; OAI: obstructive apnea index; PGA: Patient Global Assessment; RCT: randomized controlled trial.

a Patients in the treatment group who had reached 36 months of follow-up prior to study closure

b Patients with marked or moderate improvement in 7-point quality of life scale

Non-Comparative Studies

Abraham et al (2015)¹¹ and Jagielski et al (2016)⁹ presented 6-month and 12-month results from a U.S. Food and Drug Administration regulated feasibility study of 47 patients with CSA of various etiologies who received phrenic nerve stimulation with the remedē system (Table 8). Sleep disorder parameters were measured by polysomnography, through 12 months, with an optional sleep testing at 18 months. quality of life was measured on a 7-point scale, with patients answering the question, "How do you feel today compared with how you felt before having your device implanted?" CSA etiologies included HF (79%), other cardiac (13%), and opiate use (4%). Three deaths occurred during the study period, none attributed to the intervention. Five experienced serious adverse events, 3 at the beginning of the study (2 [hematoma, migraine] due to implantation procedure and 1 chest pain), and 2 during 12-months follow-up (pocket perforation and lead failure). A summary of sleep metric and quality of life results are presented in Table 9.

Wang et al (2023) conducted a prospective, non-randomized study in a small cohort who was enrolled in the Pivotal Trial.²⁴ Individuals with CSA with HF (N=9) were enrolled. Comparing pre- and post-treatment, there was a reduction in AHI (41 ± 18 e/h vs. 29 ± 25 e/h; $p=.02$) and increase in mean arterial oxygen saturation (SaO₂) ($93 \pm 1\%$ vs. $95 \pm 2\%$; $p=.03$). This study was limited because of its small sample size and it only investigated the effects of treatment over two nights of therapy. Randomized, long-term studies are necessary to better assess the effect of treatment on individuals with CSA and HF.

Table 8. Summary of Non-Comparative Study Characteristics

Study	Country	Participants	Follow-Up
Abraham (2015) ¹¹ and Jagielski (2016) ⁹	Germany, Italy, Poland, United States	Adult patients with a history of sleep apnea, predominantly CSA rather than OSA, and an AHI >20 events/hour	12 months (optional 18 months)

AHI: Apnea-Hypopnea Index; CSA: central sleep apnea; OSA: obstructive sleep apnea.

Table 9. Summary of Non-Comparative Study Results^{11,9}

Outcome	Baseline (N=47) mean \pm SD	3 months (N=47) mean \pm SD	6 months (N=41) mean \pm SD	12 months (N=41) mean \pm SD	18 months (N=17) mean \pm SD
AHI, events/hour	49.9 \pm 14.6	22.4 \pm 13.6	23.8 \pm 13.1	27.5 \pm 18.3 ^b	24.9 \pm 13.5 ^b
CAI, events/hour	28.0 \pm 14.2	4.7 \pm 8.6	4.6 \pm 7.4	6.0 \pm 9.2 ^b	4.8 \pm 5.8 ^b
OAI, events/hour	3.0 \pm 2.9	3.9 \pm 4.7	3.9 \pm 5.4	4.5 \pm 6.0	5.6 \pm 6.2
4% ODI, events/hour	45.2 \pm 18.7	21.6 \pm 13.7	23.1 \pm 13.1	26.9 \pm 18.0 ^b	25.2 \pm 13.7 ^b
Arousal index, events/hour	36.2 \pm 18.8	23.7 \pm 10.6	25.1 \pm 12.5	32.1 \pm 15.2	26.8 \pm 9.2
QOL, % improvement from baseline ^a	NA	70.8%	75.6%	83.0%	NR

^a Patients with marked or moderate improvement in 7-point quality of life scale

^b $p<.006$ compared to baseline

AHI: Apnea-Hypopnea Index; CAI: central apnea index; NA: not applicable; NR: not reported; OAI: obstructive apnea index; ODI: oxygen desaturation index; QOL: quality of life; RCT: randomized controlled trial; SD: standard deviation.

Fox et al (2017) presented data on long-term durability of the remedē System, measuring battery lifetime, device exchangeability, lead position stability, and surgical accessibility.⁸ Three consecutive patients, mean age 75.7 years, with CSA and HF with preserved ejection fraction were implanted with the remedē phrenic nerve stimulation device due to intolerability of conventional mask therapy. Implantation occurred in 2011 and the patients were followed for 4 years. Mean battery life duration was 4.2 ± 0.2 years. Therapy was well tolerated by the patients, with improvements sustained in AHI, oxygen desaturation index, and quality of life (measured by ESS). Mean device replacement procedure time was 23 minutes, under local anesthesia, with a 2-day hospital stay.

Section Summary: Phrenic Nerve Stimulation for Central Sleep Apnea

Evidence for the use of phrenic nerve stimulation therapy for the treatment of CSA consists of one RCT and observational studies. In the RCT, all patients were implanted with the phrenic nerve stimulation device, with the device activated in the intervention group at 1 month post implantation and activated in the control group at 6 months post implantation. The RCT provided 6 month comparative analyses showing significant improvements in sleep metrics as well as quality of life measures among patients with the activated stimulation device compared with patients receiving the inactivated device. Patients in the activated device arm were followed for 12 months, with analyses showing sustained significant improvements from baseline in sleep metrics and quality of life. A subgroup analyses was conducted on the subgroup of patients with HF, combining 6- and 12-month data from patients in the intervention group and 12- and 18-month data from the control group. Results from the subgroup analyses of patients with HF showed significant improvements in sleep metrics and quality of life at 12 months. An invasive procedure would typically be considered appropriate only if nonsurgical treatments had failed, but there is very limited data in which phrenic nerve stimulation was evaluated in patients who had failed the current standard of care, positive airway pressure or respiratory stimulant medication.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Sleep Medicine

The American Academy of Sleep Medicine (2012) published a guideline on the treatment of central sleep apnea (CSA), based on the results of a literature review and meta-analysis.²⁵ Moderate evidence supported the use of continuous positive airway pressure or adaptive servo-ventilation to treat CSA related to congestive heart failure. Limited evidence was

available for the use of positive airway pressure therapy (continuous positive airway pressure, bilevel positive airway pressure, adaptive servo-ventilation) to treat primary CSA; however, there is potential for ameliorating central respiratory events, risks are low, and the therapies are readily available. The use of phrenic nerve stimulation devices were not discussed in the guideline. An update to the guideline, published in 2016,²⁶ adjusted the previous guideline, to warn that adaptive servo-ventilation is not recommended for individuals with CSA related to congestive heart failure with ejection fraction <45%. The use of phrenic nerve stimulation as a treatment option was not addressed in the guideline.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov did not identify any ongoing or unpublished trials that would likely influence this review.

Regulatory Status

In October 2017, the remedē System (Respicardia, Inc. [now Zoll Medical]; Minnetonka, MN) was approved by the FDA through the premarket approval application process (PMA #P160039). The approved indication is for treatment of moderate to severe CSA in adults. Follow-up will continue for 5 years in the post-approval study. FDA product code: PSR.

Government Regulations

National:

There is no NCD related to this topic.

Local:

There is no LCD related to this topic.

The following codes were not listed as payable by the 2025 Physician Fee Schedule

33276, 33277, 33278, 33279, 33280, 33281, 33287, 33288, 93150, 93151, 93152, 93153

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

Phrenic Nerve Stimulation and Diaphragm Pacing

References

1. Donovan LM, Kapur VK. Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. *Sleep*. Jul 01 2016; 39(7): 1353-9. PMID 27166235
2. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N Engl J Med*. Sep 17 2015; 373(12): 1095-105. PMID 26323938
3. Wang Y, Huang Y, Xia M, et al. Effect of phrenic nerve stimulation on patients with central sleep apnea: A meta-analysis. *Sleep Med Rev*. Aug 2023; 70: 101819. PMID 37467524
4. Oldenburg O, Costanzo MR, Germany R, et al. Improving Nocturnal Hypoxemic Burden with Transvenous Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. *J Cardiovasc Transl Res*. Apr 2021; 14(2): 377-385. PMID 32789619
5. Costanzo MR, Goldberg LR, Ponikowski P, Augostini R, Stellbrink C, Abraham W. Phrenic nerve simulation for central sleep apnea is effective and safe in the presence of concomitant cardiac devices. *J Card Fail*; Aug 2018; 24(8):S17-8.
6. Costanzo MR, Goldberg LR, Ponikowski P, Augostini R, Stellbrink C, Abraham W. Phrenic nerve simulation for central sleep apnea is effective and safe in the presence of concomitant cardiac devices. *J Card Fail*; Aug 2018; 24(8):S17-8.
7. Zhang X, Ding N, Ni B, et al. Safety and feasibility of chronic transvenous phrenic nerve stimulation for treatment of central sleep apnea in heart failure patients. *Clin Respir J*. Mar 2017; 11(2): 176-184. PMID 26072733
8. Fox H, Bitter T, Horstkotte D, et al. Long-Term Experience with First-Generation Implantable Neurostimulation Device in Central Sleep Apnea Treatment. *Pacing Clin Electrophysiol*. May 2017; 40(5): 498-503. PMID 28211952
9. Jagielski D, Ponikowski P, Augostini R, et al. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedē® System. *Eur J Heart Fail*. Nov 2016; 18(11): 1386-1393. PMID 27373452
10. Costanzo MR, Ponikowski P, Javaheri S, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *Lancet*. Sep 03 2016; 388(10048): 974-82. PMID 27598679
11. Abraham WT, Jagielski D, Oldenburg O, et al. Phrenic nerve stimulation for the treatment of central sleep apnea. *JACC Heart Fail*. May 2015; 3(5): 360-369. PMID 25770408
12. Ponikowski P, Javaheri S, Michalkiewicz D, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. *Eur Heart J*. Apr 2012; 33(7): 889-94. PMID 21856678
13. Zhang XL, Ding N, Wang H, et al. Transvenous phrenic nerve stimulation in patients with Cheyne-Stokes respiration and congestive heart failure: a safety and proof-of-concept study. *Chest*. Oct 2012; 142(4): 927-934. PMID 22302299
14. Costanzo MR, Augostini R, Goldberg LR, et al. Design of the remedē System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. *J Card Fail*. Nov 2015; 21(11): 892-902. PMID 26432647
15. Costanzo MR, Ponikowski P, Javaheri S, et al. Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. *Am J Cardiol*. Jun 01 2018; 121(11): 1400-1408. PMID 29735217
16. Fox H, Bitter T, Horstkotte D, et al. Long-Term Experience with First-Generation Implantable Neurostimulation Device in Central Sleep Apnea Treatment. *Pacing Clin Electrophysiol*. May 2017; 40(5): 498-503. PMID 28211952

17. Baumert M, Immanuel S, McKane S, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnea reduces episodic hypoxemic burden. *Int J Cardiol.* May 01 2023; 378: 89-95. PMID 36841294
18. Baumert M, Linz D, McKane S, et al. Transvenous phrenic nerve stimulation is associated with normalization of nocturnal heart rate perturbations in patients with central sleep apnea. *Sleep.* Sep 08 2023; 46(9). PMID 37284759
19. Hartmann S, Immanuel S, McKane S, et al. Transvenous phrenic nerve stimulation for treating central sleep apnea may regulate sleep microstructure. *Sleep Med.* Jan 2024; 113: 70-75. PMID 37988861
20. Samii S, McKane S, Meyer TE, et al. Analysis by sex of safety and effectiveness of transvenous phrenic nerve stimulation. *Sleep Breath.* Mar 2024; 28(1): 165-171. PMID 37436669
21. Abraham WT, Oldenburg O, Lainscak M, et al. Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure. *ESC Heart Fail.* Feb 2025; 12(1): 80-86. PMID 39422417
22. Costanzo MR, Ponikowski P, Coats A, et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. *Eur J Heart Fail.* Dec 2018; 20(12): 1746-1754. PMID 30303611
23. Hill L, Meyer T, McKane S, et al. Transvenous phrenic nerve stimulation to treat central sleep apnoea in patients with heart failure may improve sleep, quality of life, and symptoms. *Eur J Cardiovasc Nurs.* Jul 19 2023; 22(5): 489-497. PMID 36125322
24. Wang Y, Schoebel J, Han J, et al. Phrenic nerve stimulation for the treatment of central sleep apnea in patients with heart failure. *Sleep Breath.* Jun 2023; 27(3): 1027-1032. PMID 35978055
25. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep.* Jan 01 2012; 35(1): 17-40. PMID 22215916
26. Aurora RN, Bista SR, Casey KR, et al. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. *J Clin Sleep Med.* May 15 2016; 12(5): 757-61. PMID 27092695
27. Wisconsin Physicians Service Insurance Corporation. Local Coverage Article: Billing and Coding: Category III Codes (A56902). Original effective date: 08/29/2019, Revision effective date: 3/28/24.
28. Hartmann S, Immanuel S, McKane S, Linz D, Parrino L, Baumert M. Transvenous phrenic nerve stimulation for treating central sleep apnea may regulate sleep microstructure. *Sleep Med.* 2024;113:70-75. doi:10.1016/j.sleep.2023.11.005
29. Hill L, Meyer T, McKane S, Lainscak M, Ahmed QA. Transvenous phrenic nerve stimulation to treat central sleep apnoea in patients with heart failure may improve sleep, quality of life, and symptoms. *Eur J Cardiovasc Nurs.* 2023;22(5):489-497. doi:10.1093/eurjcn/zvac086

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 5/13/25, the date the research was completed.

Joint BCBSM/BCN Medical Policy History//

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
11/1/20	8/18/20		Joint policy established
11/1/21	8/17/21		Routine maintenance Ref 14,15 added – inquiry on behalf of Respicardia
11/1/22	8/16/22		Routine maintenance Ref 7 added (ls)
11/1/23	8/15/23		Routine maintenance (jf) Vendor Managed: NA
3/1/24	12/19/23		2024 Annual Code Update (jf) <ul style="list-style-type: none"> Add new codes 33276, 33277, 33278, 33279,33280, 33281, 33287, 33288 as E/I set has been created to represent phrenic nerve stimulation services for the treatment of moderate to severe central sleep apnea. Added new codes 93150, 93151, 93152, 93153 as E/I. The new Category I codes are replacing Category III codes 0424T-0436T which are being deleted. Vendor Managed: NA
11/1/24	8/20/24		Routine maintenance (jf) Vendor Managed: NA Ref added: 3,17,18,19,20,22,23,27,and 28
11/1/25	8/19/25		Routine maintenance (jf) Vendor Managed: NA Added Ref: 21 <ul style="list-style-type: none"> Description added and background separated, movement of policy language and formatting to assist with flow MPS edited: New Format language added, There is

			insufficient evidence to determine that the technology results in an improvement in net health outcomes.
--	--	--	--

Next Review Date: 3rd Qtr, 2026

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: PHRENIC NERVE STIMULATION FOR CENTRAL SLEEP APNEA

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered
BCNA (Medicare Advantage)	See Government Regulations section
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.